Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression

The growing interest in new classes of anti‐cancer agents, such as molecularly‐targeted therapies and immunotherapies with modes of action different from those of cytotoxic chemotherapies, has changed the dose‐finding paradigm. In this setting, the observation of late‐onset toxicity endpoints may be...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrillon, Anaïs, Chevret, Sylvie, Lee, Shing M., Biard, Lucie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691552/
https://www.ncbi.nlm.nih.gov/pubmed/36259523
http://dx.doi.org/10.1002/sim.9591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691552/
https://www.ncbi.nlm.nih.gov/pubmed/36259523
http://dx.doi.org/10.1002/sim.9591

Ejemplares similares